Phaseline

Companies › Actuate Therapeutics

Actuate Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 2, 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Elraglusib (ING-41)
Glycogen synthase kinase-3 beta inhibitor
GSK3BPhase 2Cancer; Pancreatic Adenocarcinoma; Salivary Gland Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03678883Elraglusib (ING-41)Phase 2CancerOncologyJun 2026
NCT05077800Elraglusib (ING-41)Phase 2Pancreatic AdenocarcinomaOncologyDec 2026
NCT05010629Elraglusib (ING-41)Phase 2Salivary Gland CancerOncologyApr 2027
NCT06896188Elraglusib (ING-41)Phase 1Pancreatic AdenocarcinomaOncologyMar 2028

From the company's SEC filings

Cash of $4m on 2026-06-30; operating cash outflow about $19m a year; runway about 3 months at that burn, to Sep 2026; 0 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

GSK3B (1)

Companies with the same targets

AMO Pharma Alzamend Neuro

Companies built like this

Oncolytics Biotech Cardiff Oncology TuHURA Biosciences Inhibrx Biosciences Vasgene Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.